Top Markets
#1 Status Status +18.91%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +18.45%
#4 Ontology Gas Ontology Gas +11.14%
#5 Fake World Assets Fake World Assets +9.28%
#6 DMT-NAT DMT-NAT +9.09%
#7 o1.exchange o1.exchange +7.20%
#8 Provenance Blockchain Provenance Blockchain +7.18%
#9 Nillion Nillion +7.03%
#10 Pons Pons +6.71%
Coin of the day
Status Status
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Kineta, Inc. Kineta, Inc.

Kineta, Inc.

KA
Rangering i aksjer #34153
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing... Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Aksjekurs
$0.617
Sist synkronisert: 2024-10-14
Markedsverdi
$6.13M
Endring (1 dag)
0.49%
Endring (1 år)
0.00%
Land
US
Handel Kineta, Inc. (KA)

Kategori

Healthcare
Inntekter for Kineta, Inc. (KA)
Inntekter i Mar 2025 TTM: $-7.68M
Ifølge Kineta, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-7.68M. I 2023 hadde selskapet et resultat på $-14.08M, en økning sammenlignet med resultatet i 2022, som var $-63.45M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Kineta, Inc. fra 2015 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-7.68M -55.17%
2024 $-17.13M 21.71%
2023 $-14.08M -77.82%
2022 $-63.45M 436.96%
2021 $-11.82M 66.16%
2020 $-7.11M -87.97%
2019 $-59.13M -4.38%
2018 $-61.83M 4.04%
2017 $-59.43M 59.63%
2016 $-37.23M 48.69%
2015 $-25.04M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -68,774.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -25,495.78%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -39,231.85%
BE